Senseonics (NYSE:SENS) announced today that the FDA granted approval to its next-generation continuous glucose monitor system.
Germantown, Maryland-based Senseonics designed the Eversense E3, which includes proprietary sacrificial boronic acid (SBA) technology, to extend longevity to six months (180 days), having previously offered the system with a 90-day wear time.
Get the full story at our sister site, Drug Delivery Business News.
When Dr. Fran Kaufman began her career in the late 1970s, diabetes management consisted of urine testing and animal insulin.
At that point, it had not been proven that managing glucose actually mattered, according to Kaufman, and proof didn’t come until 1992 with the conclusion of the DCCT study.
“I’ve seen a lot of innovation,” said Kaufman, chief medical officer at continuous glucose monitoring technology developer Senseonics (NYSE:SENS).
She’s been involved in innovation as well, the latest being the 180-day Senseonics Eversense continuous glucose monitor (CGM), for which FDA approval could be coming very soon.
Get the full story at our sister site, Drug Delivery Business News.
Senseonics (NYSE:SENS) announced that it anticipates a decision from the FDA regarding the approval of its new CGM system within weeks.
The company is seeking a premarket approval supplement for the next-generation Eversense 180-day implantable continuous glucose monitoring (CGM) system. Data presented earlier this year demonstrated strong accuracy, with the next-generation Eversense matching performance levels compared to the current 90-day sensor available in the U.S., but with reduced calibration, down to one per day, with the duration extended to 180 days.
Get the full story at our sister site, Drug Delivery Business News.
Senseonics (NYSE:SENS) announced today that its Eversense NOW remote monitoring app for Android received CE mark approval.
Germantown, Maryland-based Senseonics already received such approval for the Eversense NOW iOS platform and can now offer it in Europe on the Android operating system. The company expects to make the Eversense NOW remote monitoring app for Android available in the first quarter of 2022 on the Google Play Store.
Get the full story at our sister site, Drug Delivery Business News.
World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes.
This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease.
Some of those treatments involve insulin, which was discovered as a treatment for diabetes in 1922 and remains a vital part of the standard of care. World Diabetes Day falls on Nov. 14 because it is the birthday of Frederick Banting, one of the scientists involved in discovering insulin as a treatment for diabetes.
However, while many medtech companies look for ways to make insulin accessible and efficient in treating diabetes, others are innovating treatment avenues outside of insulin. Regardless of the path chosen, all have created intriguing options for managing and treating diabetes. Here are seven innovations in diabetes treatment that are worth keeping an eye on:
Next>>World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes.
This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease.
Some of those treatments involve insulin, which was discovered as a treatment for diabetes in 1922 and remains a vital part of the standard of care. World Diabetes Day falls on Nov. 14 because it is the birthday of Frederick Banting, one of the scientists involved in discovering insulin as a treatment for diabetes.
However, while many medtech companies look for ways to make insulin accessible and efficient in treating diabetes, others are innovating treatment avenues outside of insulin. Regardless of the path chosen, all have created intriguing options for managing and treating diabetes. Here are seven innovations in diabetes treatment that are worth keeping an eye on:
Next>>World Diabetes Day — Nov. 14 — centers around raising awareness for those who live every day with diabetes.
This year, that aim remains the same, and medical technology companies all over the world continue to look for ways to help manage the metabolic disease.
Some of those treatments involve insulin, which was discovered as a treatment for diabetes in 1922 and remains the standard of care. World Diabetes Day falls on Nov. 14 because it is the birthday of Frederick Banting, one of the scientists who helped to discover insulin as a treatment for diabetes.
However, while many medtech companies look for ways to make insulin accessible and efficient in treating diabetes, others are innovating treatment avenues outside of insulin. Regardless of the path chosen, all have created intriguing options for helping to manage and treat diabetes. Here are seven innovations in diabetes treatment that are worth keeping an eye on:
Next>>Senseonics (NYSE:SENS) shares ticked up slightly on third-quarter results that beat the consensus earnings forecast.
The Germantown, Maryland-based company posted profits of $42.9 million, or 8¢ per share, on sales of $3.5 million for the three months ended Sept. 30, 2021, for a massive bottom-line swing out of the red on sales growth of nearly $3 million.
Get the full story at our sister site, Drug Delivery Business News.
After several weeks of high-level performance, the medtech industry saw its first dip in a while over the last seven days.
MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (Aug. 13) at 117.92 points, marking a -1.2% dip from the 119.41-point tally a week prior (Aug. 6).
Medtech’s performance continues to reflect an overall rebound from the struggles brought on by the COVID-19 pandemic, too. The industry remains well above the marks set around the height of the pandemic, having registered a 27.7% increase from the pre-pandemic high of 92.32 (set on Feb. 19, 2020). Moreover, it remains well ahead of the mid-pandemic low of 62.13 (March 23, 2020) as well, totaling an 89.8% ascent above that point.
The industry’s performance did not correlate with the overall markets this past week as the S&P 500 Index and Dow Jones Industrial Average fared almost identically, ticking up by 0.7% a…
Senseonics (NYSE:SENS) shares took a hit today on second-quarter results that missed the consensus earnings forecast.
The Germantown, Md.-based company posted losses of $180.3 million on sales of $3.3 million for the three months ended June 30, 2021, seeing its bottom line plummet from losses of just $7.5 million this time last year despite bringing in revenues more than 11 times of the tally registered in the second quarter of 2020.
Get the full story at our sister site, Drug Delivery Business News.
Senseonics (NYSE:SENS) today presented further data evaluating its next-generation Eversense continuous glucose monitoring system.
Germantown, Md.-based Senseonics presented data from the Promise study at the American Diabetes Association Virtual 81st Annual Scientific Sessions. The data adds to positive results already presented by the company at the beginning of this month that demonstrated high levels of accuracy.
Get the full story at our sister site, Drug Delivery Business News.
Senseonics (NYSE:SENS) shares ticked up before hours today on first-quarter results that beat the consensus forecast.
The Germantown, Md.-based diabetes management technology developer posted losses of -$249.5 million, or -68¢ per share, on sales of $2.8 million for the three months ended March 31, 2021, registering a massive bottom-line slide from losses of -$42.6 million this time one year ago despite increasing sales from just $36,000 year-over-year.
Get the full story at our sister site, Drug Delivery Business News.